Precision Testing Project – 2022 Online Educational Course
The complexities of solid tumours are now evident for all. A better understanding of determinants of tumour behaviour and response to treatment is gained every day, and the term “precision testing” is often used. In 2021 SPCC conducted a series of webinars and is continuing to work on this topic.
Knowledge of the tests needed and their potential role in guiding treatment choices are important topics, as are accessibility and reimbursement of these tests. From treatment target evaluation to molecular oncology and advanced genomics, precision testing is aimed at ensuring that the right treatment is administered to the right patient at the right time, leading to a better outcome. Some tests may play a role in early detection and help to avoid unnecessary treatment and reduce costs. The most unacceptable cost is the use of ineffective therapy. From the healthcare system perspective, precision testing brings more certainty on treatment outcomes and improves the sustainability and efficiency of healthcare. From the patient perspective, precision testing makes it possible to find the best available treatments and improves outcomes and quality of life.
However, due to regulatory, access and reimbursement barriers, even well-proven precision testing is not offered to all patients in Europe, not to speak of on global level. There is also a lack of the infrastructure needed to support and take advantage of genomic and molecular testing, including the development of networks to discuss the implications of the results in specific tumour boards. Even in countries where the infrastructure does exist, health care providers need more adequate information, knowledge and awareness, and patients require education and empowerment in order to ensure proper molecular characterisation of every patient’s tumour.
Dates, faculty, programme and further information about this initiative are available here.